Comparing highly purified human menopausal gonadotropin and recombinant follicle stimulating hormone in poor ovarian reserve patients undergoing intracytoplasmic sperm injection
Česká gynekologie · 2024
DOI: 10.48095/cccg2024469 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Česká gynekologie, 2024. Verfasst von Dilay Gok Korucu und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Sperm Injections, Intracytoplasmic, Menotropins, Ovarian Reserve, Follicle Stimulating Hormone.
Abstract (Originalsprache)
Objective
We aimed to compare highly purified human menopausal gonadotropin (hp-hMG) and recombinant follicle stimulating hormone (rFSH) in short antagonist in vitro fertilization (IVF) cycles of patients with poor ovarian reserve (POR). Limited research exists on this comparison in short antagonist cycles for this patient group. Materials and methods: This retrospective cohort study involved 165 POR patients aged 18–45 years who underwent IVF between 2018 and 2022. Patients were divided into two groups based on their GnRH antagonist protocol: hp-hMG (group 1 = 72) and rFSH (group 2 = 93). We compared pregnancy outcomes, number of oocytes collected, mature oocytes retrieved, mean fertilized oocytes, top quality embryos transferred, and serum estradiol (E2) and progesterone (P) levels on human chorionic gonadotropin (hCG) administration day.
Results
No significant differences were found in E2 and P levels on hCG trigger day, endometrial thickness on transfer day, stimulation duration, total oocyte number, and mature oocyte number (P > 0.05). The total gonadotropin dose was significantly higher in the rFSH group (P < 0.001). The number of top-quality embryos transferred and clinical pregnancy and live birth rates did not diff er significantly between groups (P = 0.320; P = 0.310; P = 0.652; and P = 0.662, resp.).
Conclusion
Neither hp-hMG nor rFSH showed superiority in patients with POR, indicating similar effectiveness in this population. Key words: highly purified human menopausal gonadotropin – in vitro fertilization – live birth – poor ovarian reserve – recombinant follicle stimulating hormone
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
ORCID-Profile: Dilay Gok Korucu, Humeyra Akgun, Mahmut Sami Tutar, Sukran Doğru, Oguzhan Gunenc
Zitieren
APA
Korucu, D. G., Akgun, H., Tutar, M. S., Doğru, S., & Gunenc, O. (2024). Comparing highly purified human menopausal gonadotropin and recombinant follicle stimulating hormone in poor ovarian reserve patients undergoing intracytoplasmic sperm injection. Česká gynekologie. https://doi.org/10.48095/cccg2024469
Vancouver
Korucu DG, Akgun H, Tutar MS, Doğru S, Gunenc O. Comparing highly purified human menopausal gonadotropin and recombinant follicle stimulating hormone in poor ovarian reserve patients undergoing intracytoplasmic sperm injection. Česká gynekologie. 2024. doi:10.48095/cccg2024469
BibTeX
@article{Korucu2024,
author = {Korucu, Dilay Gok and Akgun, Humeyra and Tutar, Mahmut Sami and Doğru, Sukran and Gunenc, Oguzhan},
title = {Comparing highly purified human menopausal gonadotropin and recombinant follicle stimulating hormone in poor ovarian reserve patients undergoing intracytoplasmic sperm injection},
journal = {Česká gynekologie},
year = {2024},
doi = {10.48095/cccg2024469}
}
EUVIMED